Michael Foley, Ph.D.
Board of Directors
Michael Foley, Ph.D., serves on the board of directors at Aviko and is the chief executive officer at Deerfield Discovery and Development. Michael joined Deerfield in 2018 to focus on research collaborations. Most recently, he was the CEO and Sanders Director at Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI), where he led the efforts to discover drug candidates in an academic setting. Prior to Tri-I TDI, he was director of the chemical biology platform at the Broad Institute of MIT and Harvard. Michael is the founder of Forma Therapeutics. In 2001, he founded Infinity Pharmaceuticals, and in 2000, he founded CombinatoRx. In 1999, Michael was a founding member of the Harvard Institute of Chemistry and Cell Biology and served as the head of chemical technology. He was a GlaxoSmithKline fellow at Harvard University and before that was a research chemist at GlaxoSmithKline. Michael began his career at Bristol Myers Squibb as a research chemist. He received his bachelor’s degree from St. Norbert College, his Master of Science from Utah State University and his doctorate from Harvard University.